As BRAF/MEK inhibitor therapy tends to produce faster and higher tumor shrinkage rates in the beginning than immunotherapy, in patients with high tumor burden therapy is often initiated with targeted therapy if BRAF mutation is detectable [14,15]. This evidence concerns the gene MAP2K7 and neoplasm.